smithkline lt skb aim 10 pct earn raise smithkline beckman corp say pursue three point stragey achieve 10 pct annual increase operate earn throughout remainder decade 1986 smithkline earn 521 1 mln dlrs 6 78 dlrs per share revenue 3 6 billion dlrs company say annual report nonpharmaceutical business play major role meet earn growth target fact grow faster pharmaceutical business smithkline whose major product antiulcer medication tagamet say report intend improve earn exist product expand product portfolio optimize financial resource bolster position antiulcer market tagamet meet stiff competition smithkline say strategy develop counter version tagamet bolster two joint venture one lt wellcome plc >, one pending venture japan smithkline also say allergan inc eye skin care product division one billion dlr organization next five year grow seven 10 pct annually nondilutive acquisition real possibility ," gavin herbert president eye skin care product group say report 1986 allergan worldwide sale 433 mln dlrs say smith kline french laboratory pharmaceutical unit 1986 sale 1 9 billion dlrs file food drug administration market approval number cardiovascular agent include tissue plasminogen activator next two year also say sk f u sale force 20 pct larger 1987 1 000 sale personnel smith kline also say small clinical laboratory test unit 1986 sale 373 mln dlrs perform 24 mln test year see increase employee drug test well test aid antibody smith kline say depend share price cost money may buy back share last three year buy back 25 pct share smithkline begin year new management team include new chief operate officer george ebright 